Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
PR Newswire
BOSTON, Feb. 8, 2024
Financial release accessible online
BOSTON, Feb. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2024, which ended December 30, 2023, are available on its Investor Relations website.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 8, 2024. The conference call and webcast can be accessed with the following information:
- Teleconference link: https://register.vevent.com/register/BIddeef4a5eb8d4c2d96bcf82386d2a73e
- Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
- A live webcast of the call can be accessed on Haemonetics' investor relations website or via the following link: https://edge.media-server.com/mmc/p/unynzc8w
In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.
Direct link to 3Q FY24 Earnings Release:
https://haemonetics.gcs-web.com/static-files/7edda7ff-7ea8-4178-b828-abcfcbafec7c
A replay of the conference call and webcast will be available for one year beginning on February 8, 2024, at 11:00 a.m. ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Sr. Director-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Director-Global Communications | |
(781) 356-9776 | |
josh.gitelson@haemonetics.com |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-3rd-quarter-fiscal-year-2024-earnings-release-available-on-investor-relations-website-302056960.html
SOURCE Haemonetics Corporation
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters